Raf-1 oncogenic signaling is linked to activation of mesenchymal to epithelial transition pathway in metastatic breast cancer cells

International Journal of Oncology

Volumn 40, Issue 6, 2012, Pages 1858-1864

  Leontovich, Alexey A ^a,b   Zhang, Shuya ^a   Quatraro, Cosima ^a   Iankov, Ianko ^b   Veroux, Pier Francesco ^d   Gambino, Mario W ^a   Degnim, Amy ^b   McCubrey, James ^c   Ingle, James ^b   Galanis, Evanthia ^b   D'Assoro, Antonino B ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b Mayo Clinic   (United States)

^c EAST CAROLINA UNIVERSITY   (United States)

^d UNIVERSITY OF CATANIA   (Italy)

Author keywords

Breast cancer; HER 2 Neu; Raf 1; Raf MEK MAPK pathway; Tyrosine kinase receptor

Indexed keywords

BETA CATENIN; CHEMOKINE RECEPTOR CXCR7; EARLY GROWTH RESPONSE FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; RAF PROTEIN; TRANSCRIPTION FACTOR FOXC1; TRANSFORMING GROWTH FACTOR BETA2; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER GROWTH; CELL CYCLE PROGRESSION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DISTANT METASTASIS; EPITHELIAL TO MESENCHYMAL TRANSITION PATHWAY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MESENCHYMAL TO EPITHELIAL TRANSITION PATHWAY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

BETA CATENIN; BREAST NEOPLASMS; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MAP KINASE SIGNALING SYSTEM; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS C-RAF; RECEPTOR, ERBB-2; TUMOR BURDEN;

EID: 84861768183     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1407     Document Type: Article

References (35)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics. CA Cancer J Clin 60: 277-300, 2010.
2. Li CI, Daling JR and Malone KE: Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 21: 28-34, 2003.
3. Colleoni M, Sun Z, Martinelli G, Basser RL, Coates AS, Gelber RD, Green MD, Peccatori F, Cinieri S, Aebi S, Viale G, Price KN and Goldhirsch A: The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Ann Oncol 20: 1344-1351, 2009.
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717, 2005.
5. Ring A and Dowsett M: Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11: 643-658, 2004. (Pubitemid 40065543)
6. Leung E, Kannan N, Krissansen GW, Findlay MP and Baguley BC: MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivity. Cancer Biol Ther 9: 717-724, 2010.
7. Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S and Pegram M: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27: 5538-5546, 2009.
8. Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, Jiang J, Howat WJ, Ali S and Carroll JS: Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456: 663-666, 2008.
9. Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I and Cohen PA: Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer 126: 545-562, 2010.
10. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M and Schiff R: Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68: 826-833, 2008. (Pubitemid 351206760)
11. Bartlett AI, Starcyznski J, Robson T, Maclellan A, Campbell FM, van de Velde CJ, Hasenburg A, Markopoulos C, Seynaeve C, Rea D and Bartlett JM: Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition. Am J Clin Pathol 136: 266-274, 2011.
12. Al-Azawi D, Leong S, Wong L, Kay E, Hill AD and Young L: HER-2 positive and p53 negative breast cancers are associated with poor prognosis. Cancer Invest 29: 365-369, 2011.
13. Acloque H, Ocaña OH, Matheu A, Rizzoti K, Wise C, Lovell-Badge R and Nieto MA: Reciprocal repression between Sox3 and snail transcription factors defines embryonic territories at gastrulation. Dev Cell 21: 546-558, 2011.
14. Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelialmesenchymal transitions in development and disease. Cell 139: 871-890, 2009.
15. Gupta GP and Massagué J: Cancer metastasis: building a framework. Cell 127: 679-695, 2006. (Pubitemid 44781029)
16. Foroni C, Broggini M, Generali D and Damia G: Epithelialmesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact. Cancer Treat Rev, Nov 25, 2011 (E-pub ahead of print).
17. Takebe N, Warren RQ and Ivy SP: Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition. Breast Cancer Res 13: 211, 2011.
18. Freudenberg JA, Wang Q, Katsumata M, Drebin J, Nagatomo I and Greene MI: The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp Mol Pathol 87: 1-11, 2009.
19. Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, Herold CI, Marcom PK, George DJ and Garcia-Blanco MA: Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res 9: 997-1007, 2011.
20. Scopelliti A, Cammareri P, Catalano V, Saladino V, Todaro M and Stassi G: Therapeutic implications of cancer initiating cells. Expert Opin Biol Ther 9: 1005-1016, 2009.
21. Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode RY and Bapat SA: Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 27: 2059-2068, 2009.
22. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain- Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS and Polyak K: Molecular definition of breast tumor heterogeneity. Cancer Cell 11: 259-273, 2007.
23. Ahmed MA, Aleskandarany MA, Rakha EA, Moustafa RZ, Benhasouna A, Nolan C, Green AR, Ilyas M and Ellis IO: A CD44(-)/CD24 (+) phenotype is a poor prognostic marker in early invasive breast cancer. Breast Cancer Res Treat, Nov 27, 2011 (E-pub ahead of print).
24. Olsson E, Honeth G, Bendahl PO, Saal LH, Gruvberger-Saal S, Ringnér M, Vallon-Christersson J, Jönsson G, Holm K, Lövgren K, Fernö M, Grabau D, Borg A and Hegardt C: CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer 11: 418, 2011.
25. Croker AK and Allan AL: Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDH(hi)CD44 (+) human breast cancer cells. Breast Cancer Res Treat, Aug 5, 2011 (E-pub ahead of print).
26. Reuben JM, Lee BN, Gao H, Cohen EN, Mego M, Giordano A, Wang X, Lodhi A, Krishnamurthy S, Hortobagyi GN, Cristofanilli M, Lucci A and Woodward WA: Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44+/CD24low/- cancer stem cell phenotype. Eur J Cancer 47: 1527-1536, 2011.
27. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J and Weinberg RA: The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715, 2008. (Pubitemid 351636299)
28. Korkaya H, Paulson A, Iovino F and Wicha MS: HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27: 6120-6130, 2008.
29. Soini Y, Tuhkanen H, Sironen R, Virtanen I, Kataja V, Auvinen P, Mannermaa A and Kosma VM: Transcription factors zeb1, twist and snai1 in breast carcinoma. BMC Cancer 11: 73, 2011.
30. Al Saleh S, Sharaf LH and Luqmani YA: Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition. Int J Oncol 38: 1197-1217, 2011.
31. Labelle M, Begum S and Hynes RO: Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20: 576-590, 2011.
32. Davis JM, Navolanic PM, Weinstein-Oppenheimer CR, Steelman LS, Hu W, Konopleva M, Blagosklonny MV and McCubrey JA: Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin Cancer Res 9: 1161-1170, 2003. (Pubitemid 36323726)
33. D'Assoro AB, Barrett SL, Folk C, Negron VC, Boeneman K, Busby R, Whitehead C, Stivala F, Lingle WL and Salisbury JL: Amplified centrosomes in breast cancer: a potential indicator of tumor aggressiveness. Breast Cancer Res Treat 75: 25-34, 2002.
34. D'Assoro AB, Busby R, Suino K, Delva E, Almodovar- Mercado GJ, Johnson H, Folk C, Farrugia DJ, Vasile V, Stivala F and Salisbury JL: Genotoxic stress leads to centrosome amplification in breast cancer cell lines that have an inactive G1/S cell cycle checkpoint. Oncogene 23: 4068-4075, 2004. (Pubitemid 38747937)
35. D'Assoro AB, Busby R, Acu ID, Quatraro C, Reinholz MM, Farrugia DJ, Schroeder MA, Allen C, Stivala F, Galanis E and Salisbury JL: Impaired p53 function leads to centrosome amplification, acquired ERalpha phenotypic heterogeneity and distant metastases in breast cancer MCF-7 xenografts. Oncogene 27: 3901-3911, 2008. (Pubitemid 351913635)